21st Conference on Retroviruses and Opportunistic Infections Boston MA March 3

Conference Reports for NATAP


21st Conference on Retroviruses and Opportunistic Infections Boston MA March 3 - 6, 2014

	Impact of Low CD4 Count and HIV Persistence on Endothelial Function in Patients with Low Plasma RNA - (04/22/14) CROI: Lessons from the 21st CROI - Integrating Data into Antiretroviral Treatment in the Clinic - Joseph Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (04/21/14) HIV, Chronic Inflammation, and CVD: Report back from the 2014 Conference on Retroviruses and Opportunistic Infections - Priscilla Hsue, MD Professor of Medicine, UCSF Cardiology Division - (04/07/14) Metabolics and Aging at CROI 2014 - David Alain Wohl, MD - The University of North Carolina - (04/06/14) Clinical Pharmacology at CROI 2014 Courtney V. Fletcher, Pharm.D. Dean and Professor Anthony T. Podany, Pharm.D. Post-Doctoral Fellow College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198 - (04/03/14) Osteoporosis (bone), Frailty, and Vitamin D: CROI 2014 - Todd T. Brown, MD, PhD Division of Endocrinology, Diabetes, & Metabolism Johns Hopkins University - (04/01/14) The Kidney at CROI 2014 -Christina M. Wyatt, MD Associate Professor, Medicine/ Nephrology Icahn School of Medicine at Mount Sinai New York, NY - (03/25/14) HIV Pathogenesis, Innate Defense against HIV, and HIV Cure at CROI 2014, Boston - By David Margolis MD UNC Chapel Hill & the Collaboratory of AIDS Researchers for Eradication (CARE) (03/25/14) 21st Conference on Retroviruses and Opportunistic Infections: Review - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (03/21/14) CROI 2014: Inflammation in HIV.....HIV cure, comorbidities, interventions to reduce inflammation - David H Shepp, MD Associate Professor of Medicine Hofstra-North Shore LIJ School of Medicine (03/21/14) Summary from CROI 2014 for Hepatitis HCV direct acting antivirals (DAAs) in HCV and HIV/HCV coinfection: same outcome? Which DAA regime will allow for the shortest treatment duration? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany (03/20/14) HIV Prevention at CROI 2014 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/12/14) HCV Coverage at CROI CMV Reactivation and Immune Aging in HIV-infected Individuals Virologically Suppressed on ART - (06/13/16) Liver-related death among HIV/HCV coinfected individuals, implications for the era of directly acting antivirals: CD4 & > F2 Associated with Liver Related Deaths in EuroSIDA - (04/05/14) Ritonavir-Boosted Atazanavir, Lopinavir, & Darunavir Increase HCV NS5A Inhibitor MK-8742 Levels - (04/05/14) Pharmacokinetic Interactions Between the HCV NS5A Inhibitor MK-8742 and Tenofovir (TDF), Raltegravir (RAL), and Efavirenz (EFV) - (04/05/14) Daclatasvir Pharmacokinetics in Healthy Subjects: No Clinically Relevant Drug-Drug Interaction With Either Cyclosporine or Tacrolimus - (04/03/14) CD4:CD8 Ratio Remains Significantly Depressed Despite Viral Suppression With Effective ART - (04/02/14) Favorable Adverse Event Profile of Sofosbuvir/Ribavirin Versus Standard of Care for Hepatitis C - (04/02/14) The CORE HCV Cascade a Decade Later: Looking Ahead to an IFN-free Era - (03/24/14) High Hepatitis C Infection Rate in Birth Cohort Testing of an Urban, Primary Care Clinic Population: HCV Cascade, 8.2% Prevalence - (03/24/14) Impact of Rapid Hepatitis C testing on Receipt of Hepatitis C Results in a Public STD Clinic - (03/24/14) The burden of hepatitis C infection in Pennsylvania state prisons and implications for treatment - (03/24/14) Hepatitis C Virus Incidence in the Amsterdam Cohort Study among Men who have Sex with Men; 1984-2011 - (03/24/14) The Treatment Cascade for People with Chronic Hepatitis C Virus Infection in the United States - (03/24/14) Implementation of a Hepatitis C testing program in a network of Federally Qualified Health Centers: initial results of an Academic-Community partnership - (03/24/14) The Hepatitis C Cascade of Care Among HIV Infected Patients Following Diagnosis of HCV Infection - (03/24/14) CROI 2014 March 3 - Martin Delaney Panel: Hepatitis C Virus: From Trials and Tribulation to Triumph - (03/24/14) Safety and Efficacy of IFN-free, Sofosbuvir/RBV Therapy in HIV/HCV Liver Transplanted Patients - (03/24/14) Safety and Efficacy of IFN-free, Sofosbuvir/RBV Therapy in HIV/HCV Liver Transplanted Patients - (03/24/14) Liver-related death among HIV/HCV coinfected individuals, implications for the era of directly acting antivirals - (03/24/14) Level of Alcohol Use and Advanced Hepatic Fibrosis in HIV-Infected and Uninfected Patients...."there may be no safe level of alcohol use among HIV+ & HCV+" - (03/24/14) Pill Burden and Treatment Duration Reduce Adherence to IFN-Free Hepatitis C Therapy in an Urban Cohort - (03/24/14) Telaprevir in Treatment-Experienced HIV-HCV G1 Coinfected Patients (ANRS HC26 TelapreVIH) - (03/24/14) Boceprevir for Previously Treated HCV-HIV Coinfected Patients: The ANRS-HC27 BocepreVIH Trial - (03/24/14) Boceprevir/Telaprevir-Based Therapy in HIV-Infection: Interim Analysis of a Multicenter Cohort - (03/24/14) Telaprevir Increases Ribavirin Toxicity Through eGFR Decrease in HIV-HCV Coinfected Patients - (03/24/14) PHARMACOKINETICS OF FALDAPREVIR AND ANTIRETROVIRALS IN PATIENTS WITH HIV/HCV CO-INFECTION - (03/21/14) EFFECT OF FALDAPREVIR ON ATAZANAVIR PHARMACOKINETICS IN PATIENTS WITH HIV/HCV CO-INFECTION - (03/21/14) EFFECT OF FALDAPREVIR ON RALTEGRAVIR PHARMACOKINETICS IN HEALTHY VOLUNTEERS - (03/21/14) FIB-4 Alone Proves Best Predictor of ESLD in People With HCV/HIV - written Mark Mascolini - (03/21/14) Post-SVR Liver Decompensation Rate Similar With HCV/HIV and HCV Alone - written Mark Mascolini - (03/21/14) Post-Transplant Survival Lower With HIV and HCV-1 Than With HCV-1 Alone - written by Mark Mascolini - (03/12/14) HCV Coverage at CROI - (03/10/14) Abbvie IFN-free 3 DAA Regimen in HCV Genotype 1-infected Patients on Methadone or Buprenorphine - (03/06/14) On-treatment Viral Response to MK-5172/MK-8742 ± RBV for 12 Weeks in HCV/HIV Co-infected Patients: The C-WORTHY Study - (03/06/14) Boehringer Ingelheim Announces Phase 3 SVR12 Results in HCV/HIV Co-Infected Patients Treated with Faldaprevir; New Drug Application Accepted by FDA - (03/06/14) Sofosbuvir With Ribavirin in Gt1/2/3 HCV/HIV Coinfected Patients - written by Mark Mascolini - (03/05/14) HIV Transmission Bottleneck Offers Clue to HCV Epidemic in HIV+ MSM - written by Mark Mascolini - (03/05/14) CROI: ABT-493, a Potent HCV NS3/4A Protease Inhibitor With Broad Genotype Coverage - (03/05/14) CROI: ABT-530, an HCV NS5A Inhibitor With Potent Pangenotypic Activity and High Genetic Barrier to Resistance - (03/05/14) CROI: Triple-DAA Combo (a Possible 3-in-1 Pill) Yields SVRs Over 90% After 12 Weeks - written by Mark Mascolini - (03/05/14) CROI: All-Oral Combination of Daclatasvir, Asunaprevir, and BMS-791325 for HCV Genotype 1 Infection - (03/04/14) Daclatasvir in Combination With Simeprevir With or Without Ribavirin for Hepatitis C Virus Genotype 1 Infection - (03/04/14) All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV (PHOTON-1) - (03/04/14) Three-DAA Regimen (Abbvie) Achieves 99% SVR12 Rates in HCV Genotype 1b Naives - written by Mark Mascolini - (03/04/14) Simeprevir Plus PegIFN/RBV Yields 74% SVR12 in HCV/HIV Patients - written by Mark Mascolini - (03/04/14) SVR12 72% With Faldaprevir Plus PegIFN/RBV in Naives With HCV/HIV - written by Mark Mascolini - (03/04/14) Combination Oral, Hepatitis C Antiviral Therapy for 6 or 12 Weeks: Results of the SYNERGY Trial - (03/04/14) Simeprevir plus PegIFN/ribavirin in HCV genotype-1/HIV-1 co-infection (Study C212) - (03/04/14) Double or Triple DAA Therapy for HCV-1 Yields 95-100% SVRs in 6 or 12 Weeks (SYNERGY Study) - written by Mark Mascolini - (03/04/14) PEARL III: SVR ≥99% AFTER 12 WKS OF ABT-450/R/267 + ABT-333 ± RBV IN TREATMENT-NAIVE HCV GT1B INFECTION - (03/04/14) Pediatrics Effective Exposure to Atazanavir during Pregnancy, Regardless of Tenofovir Use - (04/01/14) Prevalence of Congenital Anomalies in Infants With In Utero Exposure to Antiretrovirals - (04/01/14) Congenital Anomalies and in utero Antiretroviral Exposure in HIV-exposed Uninfected Infants - (04/01/14) Abnormal fatty acid oxidation in HIV-exposed, uninfected neonates in the US - (04/01/14) Bioequivalence of Two Pediatric Formulations Vs Adult Tablet Formulation of Cobicistat - (04/01/14) Bioequivalence of Two Pediatric Formulations Vs Adult Tablet Formulation of Elvitegravir - (04/01/14) Safety Pharmacokinetics and Efficacy of Dolutegravir in Treatment Experienced HIV + Children - (04/01/14) Safety and Efficacy of Dolutegravir in HIV Treatment-Experienced Adolescents: 48-Week Results - (04/01/14) Osteoporosis (bone), Frailty, and Vitamin D: CROI 2014 - (04/01/14) Bone Coverage at CROI Mechanism of Bone Disease in HIV and HCV: Impact of Tenofovir Exposure and Severity of Liver Disease - (04/01/14) Newborns Exposed to TDF in Utero Have Lower Bone Mineral Content in US - written by Mark Mascolini - (03/06/14) Rosuvastatin Improves Hip Bone Mineral Density but Worsens Insulin Resistance - (03/07/14) Vitamin D/Calcium Supplements Reduce Bone Loss by 50% When Starting EFV/TDF/FTC - written by Mark Mascolini - (03/10/14) Bone quality determination by ultrasonometry in young South African HIV-infected children - (03/10/14) Geriatric Syndromes are Common Among Older HIV-Infected Adults: in this group over age 50, 50% of participants had frailty or pre-frailty at higher frequencies than HIV-negatives" - (03/10/14) Low Bone Mineral Density among Ugandan HIV infected patients on failing first line Antiretroviral Therapy; a sub-study of the EARNEST trial - (03/10/14) Lower Newborn Bone Mineral Content (BMC) Associated with Maternal Use of Tenofovir Disoproxil Fumarate (TDF) - (03/10/14) Comparison of Two Doses of Zoledronic Acid for the Treatment of Osteoporosis in HIV Infected Patients. Results of a Randomized Open Label Study (VIHZOL Study) - (03/10/14) Longitudinal Changes in Free Testosterone among Older HIV-infected and HIV-uninfected Men: "FT decreased similarly over a 6-year interval in older HIV infected and HIV-uninfected men" - (03/10/14) Frailty, Inflammation and Mortality among Aging HIV-Infected and At-Risk Injection Drug Users - (03/10/14) Atazanavir/Cobicistat Fixed-Dose Combination is Bioequivalent to the Separate Agents - (03/10/14) Hand osteoarthritis, a joint disorder frequent and more severe HIV-1 patients : METAFIB OA Study - (03/10/14) Low Bone Mineral Density is Associated with Increased Risk of Incident Fracture in HIV-infected Adults "highlighting the potential value of DEXA screening in this population"......median age 42[35-48]....36% osteopenia/2.9% osteoporosis - (03/10/14) Bone Density Changes after Antiretroviral Initiation with Protease Inhibitors or Raltegravir - (03/10/14) New Fracture Risk and FRAX 10-Year Probability of Fracture in HIV-infected Adults - (03/10/14) Renal & Kidney Coverage at CROI HIV-Immune Complex Kidney Disease: Risk Factors and Progression to End-Stage Kidney Disease - (03/12/14) A Chronic Kidney Disease Risk Score to Determine Tenofovir Safety in a Prospective Cohort of HIV+ Male Veterans - (03/12/14) End-stage kidney disease and kidney transplantation in HIV positive patients - (03/12/14) Stopping TDF Before Renal Impairment Boosts Chance of Improving eGFR - written by Mark Mascolini - (03/12/14) HIV Coverage at CROI ART in Earliest Stage of HIV Infection Preserves Cells That Maintain Gut Barrier - reverses activation...."argues for early & aggressive ART" - Mark Mascolini (08/11/14) NOVEL INTERVENTIONS TO TARGET INCREASED INFLAMMATION IN HIV-INFECTED INDIVIDUALS - (06/05/14) A Multiple Dose Study of Raltegravir Formulations - (05/27/14) Using HIV Networks to Inform Real Time Prevention Interventions - (05/02/14) Natural History of HIV-related Anal Dysplasia: A Multi-state Modeling Analysis - (04/28/14) Drug Resistance Mutations in Treatment-Naïve HIV-Infected Patients 2000-2013; [Integrase Mutations Transmitted Low (1)] - (04/21/14) GSK1265744 Demonstrates Robust in Vitro Activity Against Various Clades of HIV-1 - (04/21/14) Is there continued evidence for an association between abacavir and myocardial infarction risk? - (04/07/14) Inflammation in Acute HIV Infection Correlates with Blood and Gut CD4 T-cell Loss and HIV Viral Burden - (04/05/14) CMV and HIV: A Double Hit On the CD4/CD8 Ratio - (04/04/14) CD4:CD8 Ratio Remains Significantly Depressed Despite Viral Suppression With Effective ART - (04/02/14) A Low CD4/CD8 Ratio During Effective ART Predicts Immunosenescence and Morbidity/Mortality - (04/02/14) PrEP at CROI, Uptake - MSM, IDUs, Meth Use - (04/02/14) Pharmacokinetics, Efficacy and Safety of an Integrase Inhibitor-Based Single-Tablet Regimen in HIV-Infected Treatment-Naïve Adolescents - (04/01/14) Sex-related Inflammatory Marker Changes Pre and Post Antiretroviral Treatment (ART) Initiation - (04/01/14) Rilpivirine pharmacokinetics in HIV-1-infected adolescents: a substudy of PAINT (Phase II trial) - (04/01/14) HIV-replication control rates needed to prevent Neurocognitive Performance (NP) decline - (04/01/14) Rosuvastatin Reduces Immune Activation and Inflammation in Treated HIV Infection - (03/28/14) Rosuvastatin Lowers Cystatin C in HIV-infected Subjects on Antiretroviral Therapy: SATURN-HIV - (03/28/14) Atazanavir and Tenofovir Attenuate the Benefit of Antiretroviral Therapy on Cystatin C: ACTG A5224s - (03/28/14) Implementation of PrEP in STD Clinics and a Community Health Center: High Uptake and Drug Levels among MSM in the Demo Project - (03/28/14) Willingness to Use Pre-Exposure Prophylaxis Among Community-Recruited Injection Drug Users - (03/28/14) Early Adopters: Socio-demographic and Behavioral Correlates of Chemoprophylaxis Use in a Recent National Online Sample of Men who have Sex with Men in the U.S. - (03/28/14) PrEP Interest, Uptake and Adherence among Young Men Who Have Sex with Men (YMSM) in the United States - (03/28/14) Contingency Management Facilitates PEP Completion among Stimulant-Using MSM - (03/28/14) HIV Infection and the Risk of Cardiovascular Disease in Women - (03/28/14) HIV Infection and the Risk of Cardiovascular Disease in Women - (03/26/14) Faster Lung Function Decline With HIV Linked to sCD14 Activation Marker - written Mark Mascolini - (03/21/14) Spine/Hip Bone Density Drops More in 96 Weeks With PIs Than With Raltegravir - written Mark Mascolini - (03/21/14) Antiviral Therapy and Smoking Associated with Coronary Vessel Wall Thickening in HIV-Infected Youth - (03/21/14) Lower CD4 Count, Detectable Viral Load, & Traditional CVD Risk Factors are Associated with Increased Risk of Primary Myocardial Infarction in the CNICS cohort....IDU associated with secondary MI - (03/21/14) Inflammation/Viral Replication/HIV Persistence....Reservoirs....Anti-Inflammation HIV Cure Strategies....VX-765, a small-molecule inhibitor of caspase-1, a potential anti-inflammatory drug/Cure Strategy to reduce reservoir?????......IP-10.... anti-inflammatory/HIV Cure strategy - (03/21/14) Abdominal Obesity, Inflammation, Immune Activation and Neurocognitive Impairment - (03/19/14) Blood Cell Indices and Neurocognitive Impairment in the HAART Era: A CHARTER Study - (03/19/14) Determinants of Cognitive Impairment in HIV-positive Men on cART and Uninfected Controls: HIV, immune activation - (03/19/14) HIV-1 Replication in Central Nervous System Increases over Time on Protease Inhibitor Only Therapy - (03/19/14) Impact of Smoking on Life Expectancy among HIV-Infected Individuals: The ART Cohort Collaboration - (03/19/14) Number and Diversity of Gut Microbes Lower With HIV and Tied to Activation - written by Mark Mascolini - (03/19/14) Lower CD4 Nadir Linked to Geriatric Syndromes in 50-or-Older People - written by Mark Mascolini - (03/19/14) Impact of Plasma HIV RNA on Neurocognitive Decline --and Difference With PIs vs NNRTIs - written by Mark Mascolini - (03/18/14) Greater Bone Deficits Seen in Young US Men Infected at Birth Versus in Adolescence....bone senescence - written by Mark Mascolini - (03/18/14) Higher Lipids Raise Acute MI Risk 22% to 64% in Untreated HCV RNA+ Veterans - written by Mark Mascolini - (03/18/14) One Quarter of HIV+ Smoker Group Has COPD--Risk Lower With Higher CD4s - written by Mark Mascolini - (03/18/14) More Life Years Lost Through Smoking Than HIV in 18,000-Person Analysis - written by Mark Mascolini - (03/18/14) Low/Moderate Alcohol Drinking Trims Heart Disease-Free Death Risk in HIV+ Swiss - written by Mark Mascolini - (03/18/14) Partner Support Does Not Improve Second-Line Response in Randomized Trial - written by Mark Mascolini - (03/18/14) Three ART Regimens Don't Differ in 144-Week "Target Not Detected" Response - written by Mark Mascolini - (03/18/14) Impact of Low-Level Viremia on Clinical and Virological Outcomes in Treated HIV-Infected Patients - (03/14/14) Cancers in HIV+ at CROI - (03/14/14) Correlation between atazanavir concentrations, clinical covariates and side effects - (03/14/14) Monthly GSK744 long-acting injections protect macaques against repeated vaginal SHIV exposures - (03/14/14) Impact of Smoking on Risk of Cancer among HIV patients Compared to the Background Population - (03/14/14) GSK1265744 Long-Acting Protects Macaques against Repeated High-Dose Intravaginal Challenges & Depo Provera-treated - (03/14/14) The Clinical Impact of Viral Load Copy Years in Antiretroviral-Naïve HIV Seroconverters - (03/14/14) Cumulative Viral Load Predicts All-cause and AIDS-related Mortality After Initiation of ART - (03/14/14) Brisk Walking Improves Inflammatory Markers in cART-Treated Patients - (03/14/14) Physical Function Impairment on Quality of Life among Persons Aging with HIV Infection - (03/14/14) Dolutegravir Regimen Statistically Superior to Efavirenz/Tenofovir/Emtricitabine: 96-Week Results From the SINGLE Study (ING114467) - (03/12/14) Dolutegravir in the French Named Patient Program* in Integrase HIV-2 Resistant Infected Patients - (03/12/14) Switch from NNRTI plus FTC/TDF to Elvitegravir/C/F/TDF Maintains HIV Suppression and is Well-Tolerated - (03/12/14) Simplification of PI + RTV + FTC/TDF to Elvitegravir/C/F/TDF Maintains HIV Suppression and is Well-Tolerated - (03/12/14) ART in Acute Infection Limits Viral Reservoirs in Three-Group Monkey Comparison - written by Mark Mascolini - (03/12/14) Stopping TDF Before Renal Impairment Boosts Chance of Improving eGFR - written by Mark Mascolini - (03/12/14) Heavy Popper Use in Gay MACS Cohort Linked to New Heart Disease, Cancer - written by Mark Mascolini - (03/12/14) Spleen and Bone Marrow May Be Key Players in Arterial Inflammation With HIV - written by Mark Mascolini - (03/12/14) Drops in AIDS Deaths, Some non-AIDS Deaths Parallel ART Expansion in British Columbia - written by Mark Mascolini - (03/12/14) HIV Rebounds Detailed in Two Boston Stem Cell Transplant Patients - written by Mark Mascolini - (03/12/14) Cumulative Viral Load Predicts All-Cause and AIDS Death But Not Non-AIDS Death - written by Mark Mascolini - (03/10/14) Tesamorelin Lowers Hepatic Fat in HIV+ With Excess Visceral Fat - written by Mark Mascolini - (03/10/14) Arterial Inflammation Tied to High-Risk Coronary Plaques in HIV Group - written by Mark Mascolini - (03/10/14) PI Regimens Tied to Cerebral Small Vessel Disease--and CSVD Tied to HAND - written by Mark Mascolini - (03/10/14) Nearly Nil HIV Transmission Risk Without Condoms and (from Jules: in established couples) With HIV+ Partner on Suppressive ART - written by Mark Mascolini - (03/10/14) Viral Suppression Induced by Anti-PD-L1 Following ARV-Interruption in SIV-Infected Monkeys - (03/07/14) Darunavir or Atazanavir vs Raltegravir Lipid Changes are unlinked to Ritonavir Exposure: ACTG 5257 - (03/07/14) Boehringer Ingelheim Announces Phase 3 SVR12 Results in HCV/HIV Co-Infected Patients Treated with Faldaprevir; New Drug Application Accepted by FDA - (03/06/14) Very Early Combination Antiretroviral Therapy in Perinatal HIV Infection: Two Case Studies - "Mississippi" baby followup & 2nd case of infant that appears to have cleared HIV/remains on cART - (03/06/14) HIV Independently Predicts Cardiovascular Disease in US Women - written by Mark Mascolini - (03/06/14) US HIV Transmission Network Study Holds Some Surprises About Women and MSM - written by Mark Mascolini - (03/06/14) Second Swiftly Treated Baby Seems to Have Cleared HIV - written by Mark Mascolini - (03/06/14) Quadrivalent HPV Vaccine Induces Immune Memory in US Men With HIV - written by Mark Mascolini - (03/06/14) Long-Acting Integrase Inhibitor GSK744 for PrEP (Once Monthly or maybe longer) - (03/05/14) Brain Markers of Inflammation Drop to Normal With Early ART - (03/05/14) Efficacy and Tolerability of Atazanavir, Raltegravir, or Darunavir with FTC/TDF: ACTG A5257 - (03/05/14) First-Line Raltegravir (RAL) + Darunavir/Ritonavir (DRV/r) is Non-inferior to Tenofovir/Emtricitabine (TDF/FTC) + DRV/r: The NEAT 001/ANRS 143 Randomised Trial - (03/05/14) Safety and Antiviral Effect of MK-1439, a Novel NNRTI, (+Truvada®) in ART-Naive HIV Infected Patients - (03/05/14) GSK744 and Rilpivirine as Two Drug Oral Maintenance Therapy: LAI116482 (LATTE) Week 48 Results - (03/05/14) HIV-1 Attachment Inhibitor Prodrug in Antiretroviral-Experienced Subjects: Week 24 Analysis - (03/05/14) HIV Transmission Bottleneck Offers Clue to HCV Epidemic in HIV+ MSM - written by Mark Mascolini - (03/05/14) Five Cancers Diagnosed at Later Stage in People With vs Without HIV - written by Mark Mascolini - (03/05/14) Novel Network Score Tied to HIV Transmission Risk and Outcomes - written by Mark Mascolini - (03/05/14) Low CD4/CD8 Ratio Predicts non-AIDS Illness in Large Italian Cohort - written by Mark Mascolini - (03/05/14) Testosterone Falls No More With Than Without HIV Over 6 Years in MACS - written by Mark Mascolini - (03/05/14) Race, Age, and Transmission Risk Affect Viral Suppression Chances in DC Cohort - written by Mark Mascolini - (03/05/14) Viral Suppression Disparities: Race, Age, and Transmission Risk Affect Viral Suppression Chances in DC Cohort - written by Mark Mascolini - (03/05/14) Transmitted HIV Resistance Rate Close to 20% in Large Study of US MSM - written by Mark Mascolini - (03/05/14) Brain Markers of Inflammation Drop to Normal With Early ART - written by Mark Mascolini - (03/05/14) Bristol-Myers Squibb Presents Promising Phase IIb Data for Novel, Investigational Attachment Inhibitor for HIV-1 Infected Treatment-Experienced Patients - press release - (03/05/14) Abbvie IFN-free 3 DAA Regimen in HCV Genotype 1-infected Patients on Methadone or Buprenorphine - (03/06/14) On-treatment Viral Response to MK-5172/MK-8742 ± RBV for 12 Weeks in HCV/HIV Co-infected Patients: The C-WORTHY Study - (03/06/14) Boehringer Ingelheim Announces Phase 3 SVR12 Results in HCV/HIV Co-Infected Patients Treated with Faldaprevir; New Drug Application Accepted by FDA - (03/06/14) Very Early Combination Antiretroviral Therapy in Perinatal HIV Infection: Two Case Studies - "Mississippi" baby followup & 2nd case of infant that appears to have cleared HIV/remains on cART - (03/06/14) Newborns Exposed to TDF in Utero Have Lower Bone Mineral Content in US - written by Mark Mascolini - (03/06/14) HIV Independently Predicts Cardiovascular Disease in US Women - written by Mark Mascolini - (03/06/14) US HIV Transmission Network Study Holds Some Surprises About Women and MSM - written by Mark Mascolini - (03/06/14) Second Swiftly Treated Baby Seems to Have Cleared HIV - written by Mark Mascolini - (03/06/14) Quadrivalent HPV Vaccine Induces Immune Memory in US Men With HIV - written by Mark Mascolini - (03/06/14) Long-Acting Integrase Inhibitor GSK744 for PrEP (Once Monthly or maybe longer) - (03/05/14) Brain Markers of Inflammation Drop to Normal With Early ART - (03/05/14) Efficacy and Tolerability of Atazanavir, Raltegravir, or Darunavir with FTC/TDF: ACTG A5257 - (03/05/14) First-Line Raltegravir (RAL) + Darunavir/Ritonavir (DRV/r) is Non-inferior to Tenofovir/Emtricitabine (TDF/FTC) + DRV/r: The NEAT 001/ANRS 143 Randomised Trial - (03/05/14) Safety and Antiviral Effect of MK-1439, a Novel NNRTI, (+Truvada®) in ART-Naive HIV Infected Patients - (03/05/14) GSK744 and Rilpivirine as Two Drug Oral Maintenance Therapy: LAI116482 (LATTE) Week 48 Results - (03/05/14) HIV-1 Attachment Inhibitor Prodrug in Antiretroviral-Experienced Subjects: Week 24 Analysis - (03/05/14) Bristol-Myers Squibb Presents Promising Phase IIb Data for Novel, Investigational Attachment Inhibitor for HIV-1 Infected Treatment-Experienced Patients - press release - (03/05/14) Sofosbuvir With Ribavirin in Gt1/2/3 HCV/HIV Coinfected Patients - written by Mark Mascolini - (03/05/14) HIV Transmission Bottleneck Offers Clue to HCV Epidemic in HIV+ MSM - written by Mark Mascolini - (03/05/14) Five Cancers Diagnosed at Later Stage in People With vs Without HIV - written by Mark Mascolini - (03/05/14) Novel Network Score Tied to HIV Transmission Risk and Outcomes - written by Mark Mascolini - (03/05/14) Low CD4/CD8 Ratio Predicts non-AIDS Illness in Large Italian Cohort - written by Mark Mascolini - (03/05/14) Testosterone Falls No More With Than Without HIV Over 6 Years in MACS - written by Mark Mascolini - (03/05/14) Race, Age, and Transmission Risk Affect Viral Suppression Chances in DC Cohort - written by Mark Mascolini - (03/05/14) Viral Suppression Disparities: Race, Age, and Transmission Risk Affect Viral Suppression Chances in DC Cohort - written by Mark Mascolini - (03/05/14) Transmitted HIV Resistance Rate Close to 20% in Large Study of US MSM - written by Mark Mascolini - (03/05/14) Brain Markers of Inflammation Drop to Normal With Early ART - written by Mark Mascolini - (03/05/14) ABT-493, a Potent HCV NS3/4A Protease Inhibitor With Broad Genotype Coverage - (03/05/14) ABT-530, an HCV NS5A Inhibitor With Potent Pangenotypic Activity and High Genetic Barrier to Resistance - (03/05/14) Triple-DAA Combo (a Possible 3-in-1 Pill) Yields SVRs Over 90% After 12 Weeks - written by Mark Mascolini - (03/05/14) All-Oral Combination of Daclatasvir, Asunaprevir, and BMS-791325 for HCV Genotype 1 Infection - (03/04/14) Daclatasvir in Combination With Simeprevir With or Without Ribavirin for Hepatitis C Virus Genotype 1 Infection - (03/04/14) All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV (PHOTON-1) - (03/04/14) Three-DAA Regimen (Abbvie) Achieves 99% SVR12 Rates in HCV Genotype 1b Naives - written by Mark Mascolini - (03/04/14) Simeprevir Plus PegIFN/RBV Yields 74% SVR12 in HCV/HIV Patients - written by Mark Mascolini - (03/04/14) SVR12 72% With Faldaprevir Plus PegIFN/RBV in Naives With HCV/HIV - written by Mark Mascolini - (03/04/14) Combination Oral, Hepatitis C Antiviral Therapy for 6 or 12 Weeks: Results of the SYNERGY Trial - (03/04/14) Simeprevir plus PegIFN/ribavirin in HCV genotype-1/HIV-1 co-infection (Study C212) - (03/04/14) Double or Triple DAA Therapy for HCV-1 Yields 95-100% SVRs in 6 or 12 Weeks (SYNERGY Study) - written by Mark Mascolini - (03/04/14) PEARL III: SVR ≥99% AFTER 12 WKS OF ABT-450/R/267 + ABT-333 ± RBV IN TREATMENT-NAIVE HCV GT1B INFECTION - (03/04/14)